Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab

BACKGROUND: Eptinezumab is an anti-calcitonin gene-related peptide humanized monoclonal antibody approved for the preventive treatment of migraine in adults. The PREVAIL study demonstrated a favorable safety profile with sustained reductions in overall migraine-related burden in patients with chroni...

Descripción completa

Detalles Bibliográficos
Autores principales: Blumenfeld, Andrew, Ettrup, Anders, Hirman, Joe, Ebert, Bjarke, Cady, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264513/
https://www.ncbi.nlm.nih.gov/pubmed/35804294
http://dx.doi.org/10.1186/s12883-022-02774-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264513/
https://www.ncbi.nlm.nih.gov/pubmed/35804294
http://dx.doi.org/10.1186/s12883-022-02774-3

Ejemplares similares